|
(Chest. 1999;116:450S-454S.) © 1999 American College of Chest Physicians
Sean C. Grondin, MD and David J. Sugarbaker,
MD, FCCP
* From the Division of Thoracic Surgery,
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA.
Correspondence to: David J.
Sugarbaker, MD, FCCP, Division of Thoracic Surgery, Brigham and Women’s
Hospital, 75 Francis St, Boston, MA 02115
Study objectives: Malignant pleural
mesothelioma (MPM) is predominantly a local/regional disease that results
in a survival time that ranges from 4 to 12 months without treatment.
Single-modality therapy using surgery, chemotherapy, or radiotherapy alone
is largely ineffective. The objective of the study was presentation of the
use of pleuropneumonectomy in a multimodality treatment setting and the
results.
Design: Didactic presentation.
Setting: Academic tertiary-care
hospital.
Patients: One hundred eighty-three
patients who underwent multimodality therapy.
Interventions: Of all the single-modality
treatment approaches, pleuropneumonectomy has been associated most
consistently with long-term disease-free survival and has provided the
greatest amount of tumor cytoreduction. The technique of
pleuropneumonectomy traditionally has been linked with high perioperative
mortality and morbidity when compared with that of other cytoreductive
techniques such as pleurectomy/decortication. Recently, improvements in
operative mortality (< 5%) have been reported, largely due to improvements
in patient selection and perioperative management. Multimodality therapy,
including chemotherapy, radiotherapy, and extrapleural pneumonectomy, was
used to treat patients.
Results: Outcomes were presented for
183 patients with MPM who underwent multimodality therapy.
Conclusions: With the development of
multimodality therapy, pleuropneumonectomy followed by sequential
chemotherapy and radiotherapy has demonstrated a significant survival
benefit, especially for patients who have epithelial tumor histology,
tumor-free resection margins, and tumor-free extrapleural node status.
*** POSTED ON
MAY 21, 2004
***
|